DMAA

Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ: DMAA · FINANCIAL SERVICES · SHELL COMPANIES

$10.74

-0.19% today

Updated 2026-08-27

Market cap

$260.25M

P/E ratio

59.56

P/S ratio

—

EPS (TTM)

$0.18

Dividend yield

—

52W range

$10 – $11

Volume

0.0M

Market cap

$260.25M

P/E ratio

59.56

P/S ratio

—

EPS (TTM)

$0.18

Dividend yield

—

52W range

$10 – $11

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.7

Growth

C+

5.3

Quality

C+

3.5

Profitability

4.0

Valuation

2/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →248 stocks currently score above 75

Price targets

Analyst target

—

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-244610.00

- P/E 59.56x — expensive valuation

Key financials

Revenue Net Income Free Cash Flow

Metric	2024	2025	TTM
Revenue	—	$0.00	—
Net income	$-479.00	$5.94M	$1.73M
EPS	—	—	$0.18
Free cash flow	$-172270.00	$-539187.00	$-244610.00
Profit margin	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DMAA	$260.25M	34	5.7	3.5	4.0	5.3	—	Avoid
BRK-A	$1.08T	73	7.3	7.5	5.0	8.5	—	Strong Buy
BRK-B	$1.07T	74	7.3	7.5	5.0	8.0	—	Strong Buy
JPM	$959.50B	81	10.0	8.0	5.7	3.0	—	Exceptional Buy
V	$669.97B	68	6.7	10.0	4.3	5.0	—	Strong Buy
MA	$492.55B	70	7.3	10.0	4.3	6.0	—	Strong Buy

Smart narrative

Drugs Made In America Acquisition Corp. Ordinary Shares trades at $10.74. representing a P/E of 59.56x trailing earnings. Our Smart Value Score of 34/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.

Frequently asked questions

What is Drugs Made In America Acquisition Corp. Ordinary Shares's stock price?

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) trades at $10.74, on a P/E of 59.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is Drugs Made In America Acquisition Corp. Ordinary Shares overvalued?

Drugs Made In America Acquisition Corp. Ordinary Shares carries a Smart Value Score of 34/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

Company info

SectorFINANCIAL SERVICES

IndustrySHELL COMPANIES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE2.84%

Beta—

50D MA$10.67

200D MA$10.51

Shares out0.02B

Float0.03B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

DMAA vs BRK-A →DMAA vs BRK-B →DMAA vs JPM →Stock screener →